The largest database of trusted experimental protocols

0.1 m filters

Manufactured by Merck Group
Sourced in United Kingdom, Germany, United States

The 0.1-µm filters are a type of lab equipment used for filtration purposes. They have a pore size of 0.1 micrometers, which allows them to remove very small particles and microorganisms from liquids or gases. The filters are designed to provide efficient separation and purification of samples.

Automatically generated - may contain errors

5 protocols using 0.1 m filters

1

Optimizing Cell Preparation for Flow and Imaging Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols
Phosphate buffered saline (PBS) without calcium and magnesium was obtained from Life Technologies (Paisley, UK) and filtered through 0.1 µm filters (Merck Millipore, Billerica, MA) immediately before use. RPMI-1640 (RPMI) and ethylene diamine tetraacetic acid disodium salt (EDTA) were purchased from Sigma Aldrich (St Louis, MO). All monoclonal antibody-fluorochrome conjugates used for flow cytometry, imaging flow cytometry, cell sorting, and confocal microscopy are listed in Supplementary Table 1.
+ Open protocol
+ Expand
2

SARS-CoV-2 Virus Propagation and Inactivation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isolated SARS-CoV-2 was subsequently passaged two times in Vero E6 cells in the same DMEM as above, but with reduced FBS (2%). Virus-containing supernatants were harvested, cleared by centrifugation (300× g, 5 min, 20 °C), filtered through 0.45 µm pore size cellulose-acetate filters (Merck, Darmstadt, Germany) and stored at −80 °C. Infectious titres were determined as the 50% tissue culture infectious dose (TCID50) by endpoint titration using serial 5-fold dilutions of SARS-CoV-2 in triplicate on Vero E6 cells according to the Reed and Muench method [53 ]. SARS-CoV-2 obtained from infected Vero E6 cells was directly used for infection of Calu-3 and Caco-2 cells (described in Section 2.8). For experiments with non-infectious viruses, SARS-CoV-2 was heat inactivated at 65 °C for 20 min. Virus-cleared conditioned media was prepared by centrifugation of SARS-CoV-2 obtained from infected Vero E6 cells through a cushion of 20% (w/w) sucrose in phosphate-buffered saline (PBS) (90,000× g, 3 h, 4 °C). The supernatant was filtered three times through 0.1-µm filters (Merck, Darmstadt, Germany).
+ Open protocol
+ Expand
3

HCV RNA Transfection into Huh7.5/CD81 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
pFLJc1p7NS2Gluc2a, pFLHB/JFHGluc2a, pFLH77/JFHGluc2a and pFLJ6/JFHGluc2 were linearized, further purified with ethanol and sodium acetate, and used as templates for in vitro RNA synthesis using the RiboMAX™ Large Scale RNA Production System-T7. The synthesized HCV subgenomic RNA was treated with DNase I (Promega, Madison, WI, USA), followed by acid phenol extraction to remove any remaining template DNA. Then, 10 µg of RNA was electroporated into 2 × 105 Huh7.5/CD81 cells (270 V, 970 μF), and 48 h later, the cell culture supernatants were filtered through 0.1-µm filters (Millipore, Billerica, MA, USA) and collected.
+ Open protocol
+ Expand
4

Isolation of Urinary Microvesicles and Exosomes

Check if the same lab product or an alternative is used in the 5 most similar protocols
For isolation of urinary m/lEVs, we modified a urinary exosome extraction protocol (Fernandez-Llama et al., 2010) (link). The centrifugation conditions were identical for plasma and urine so that the size and the density of m/lEVs were similar, enabling comparison of plasma and urinary m/lEVs.
In flow cytometric analysis, the volume of urine used for each assay was 1.2 mL from each donor. In electron microscopy, the volume of urine used was 15 mL. Samples were independent and were treated individually prior to each measurement. Collected urine was centrifuged at 2,330×g for 10 min twice. The supernatant was centrifuged at 18,900×g for 30 min in a fixed-angle rotor. The m/lEV pellet obtained from centrifugation was reconstituted by vortex mixing (1-2 min) with 0.2 mL of DPBS followed by incubation with DTT (final concentration 10 mg/mL) at 37 • C for 10-15 min. The samples were centrifuged again at 18,900×g for 30 min and the supernatant was discarded. Addition of DTT, a reducing agent, reduced the formation of Tamm-Horsfall protein (THP) polymers. THP monomers were removed from m/lEVs after centrifugation. DTT-containing DPBS solutions were filtered through 0.1-µm filters (Millipore).
+ Open protocol
+ Expand
5

Flow Cytometric Analysis of m/lEVs

Check if the same lab product or an alternative is used in the 5 most similar protocols
After resuspending m/lEV pellets in 60 µL of DPBS, we added saturating concentrations of several labelled antibodies, Annexin V and normal mouse IgG and incubated the tubes in the dark, without stirring, for 15-30 min at room temperature. In one case, we added labelled antibodies directly to 60 µL of PFP for staining. We resuspended stained fractions in Annexin V binding buffer (BD Biosciences: 10 mM HEPES, 0.14 mM NaCl, 2.5 mM CaCl 2 , pH 7.4) for analysis by flow cytometry. DPBS and Annexin V binding buffer were filtered through 0.1-µm filters (Millipore). Flow cytometry was performed using a FACSVerse TM flow cytometer (BD Biosciences). The flow cytometer was equipped with 405 nm, 488 nm and 638 nm lasers to detect up to 13 fluorescent parameters. The flow rate was 12 µL /min. Forward scatter voltage was set to 381, side scatter voltage was set to 340, and each threshold was set to 200. Details of excitation (Ex.) and emission (Em.) wavelengths as well as voltages described in supplements Fig. Flow cytometry was performed using FACSuite TM software (BD Biosciences) and data were analyzed using FlowJo software. The authors have applied for the following patents for the characterization method of m/lEVs isolated from plasma and urine with a flow cytometer: JP2018-109402(plasma) and JP2018-109403(urine).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!